EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study

Sih-Yao Chen, Jheng-Yan Wu, Kuang-Ming Liao, Yu-Min Lin iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvaf014 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Sih-Yao Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, 736, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Glucagon-Like Peptide-1 Receptor Agonists, Atherosclerosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Managing patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) is challenging. While sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show cardiovascular benefits, the impact of combining these agents is unclear. This study evaluated whether adding GLP-1 RA to SGLT2i provides additional benefits in patients with both ASCVD and HF. Methods and results This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024. A total of 2 797 317 patients were identified, with 96 051 patients meeting inclusion criteria. After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE). Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74–0.83], mortality (HR 0.72; 95% CI 0.62–0.84), hospitalization (HR 0.78; 95% CI 0.73–0.83), and HFE (HR 0.77; 95% CI 0.72–0.83) vs. SGLT2i alone. Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect. Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.

Conclusions

In ASCVD and HF patients, adding GLP-1 RA to SGLT2i reduces 1-year mortality and hospitalization, warranting further investigation in diverse settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureGlucagon-Like Peptide-1 Receptor AgonistsAtherosclerosisIncretinsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeTime FactorsHospitalizationRisk AssessmentDatabases, FactualDrug Therapy, CombinationRisk Factors

Stichwörter der Autor:innen

ASCVDGLP-1RAHeart failureMACESGLT2i

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsIncretins

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, 736, Taiwan.
  • Department of Nutrition, Chi Mei Medical Center, Tainan 710, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
  • Department of Internal Medicine, Chi Mei Medical Center, Chiali, Tainan, 722, Taiwan.
  • Min-Hwei Junior College of Health Care Management, Tainan 736, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Chiali, No.606, Jialixing Jiali Dist., Tainan, 722, Taiwan.

ORCID-Profile: Yu-Min Lin

Zitieren

APA

Chen, S. Y., Wu, J. Y., Liao, K. M., & Lin, Y. M. (2025). Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf014

Vancouver

Chen SY, Wu JY, Liao KM, Lin YM. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvaf014

BibTeX
@article{Chen2025,
  author = {Chen, Sih-Yao and Wu, Jheng-Yan and Liao, Kuang-Ming and Lin, Yu-Min},
  title = {Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvaf014}
}
Kostenlos starten →